Hypoxia clinical trials at UCLA

3 in progress, 2 open to eligible people

Showing trials for

  • Pediatric Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients (P-ICECAP)

    open to eligible people ages up to 17 years

    This is a multicenter trial to establish the efficacy of cooling and the optimal duration of induced hypothermia for neuroprotection in pediatric comatose survivors of cardiac arrest. The study team hypothesizes that longer durations of cooling may improve either the proportion of children that attain a good neurobehavioral recovery or may result in better recovery among the proportion already categorized as having a good outcome.

    Los Angeles, California and other locations

  • Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients

    open to eligible people ages 18 years and up

    A multicenter, randomized, adaptive allocation clinical trial to determine if increasing durations of induced hypothermia are associated with an increasing rate of good neurological outcomes and to identify the optimal duration of induced hypothermia for neuroprotection in comatose survivors of cardiac arrest.

    Los Angeles, California and other locations

  • NKT2152, a HIF2α Inhibitor, in Patients with Advanced Clear Cell Renal Cell Carcinoma

    Sorry, in progress, not accepting new patients

    The goal of the Phase 1 portion is to identify the maximum tolerated dose (MTD) and/or the recommended doses for expansion (RDEs) of NKT2152. The Phase 2 portion will evaluate the efficacy of NKT2152 in ccRCC.

    Los Angeles, California and other locations

Our lead scientists for Hypoxia research studies include .

Last updated: